Tilray, Inc. Share Price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 784M 1.07B 62.75B | Sales 2025 * | 865M 1.18B 69.26B | Capitalization | 1.38B 1.88B 110B |
---|---|---|---|---|---|
Net income 2024 * | -211M -288M -16.89B | Net income 2025 * | -86M -118M -6.88B | EV / Sales 2024 * | 1.98 x |
Net Debt 2024 * | 178M 243M 14.25B | Net Debt 2025 * | 108M 148M 8.69B | EV / Sales 2025 * | 1.72 x |
P/E ratio 2024 * |
-5.95
x | P/E ratio 2025 * |
-12.5
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.67% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 29/04/21 |
Carl Merton
DFI | Director of Finance/CFO | - | 29/04/21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 29/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 29/04/21 |
David Clanachan
BRD | Director/Board Member | 62 | 29/04/21 |
Walter Robb
BRD | Director/Board Member | 70 | 29/04/21 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |